Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ElectromedELMD +1.21%91 5-Year Yield-on-Cost % is 0.00 as of Jul. 16, 2026. GuruFocus rates ELMD with a GF Score™ of 91/100 and a GF Value™ of $25.34 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 325 Medical Devices & Instruments companies, Electromed ranks worse than 307692% on this metric.
Electromed's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Electromed's 5-Year Yield-on-Cost % or its related term are showing as below:
ELMD's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.31 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Electromed 5-Year Yield-on-Cost % Related Terms
ELMD vs CATX, MASS, CV: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Electromed's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Electromed 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Electromed's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Electromed's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Electromed is calculated as
Electromed (ELMD) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 16, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Electromed and its competitors. According to the industry distribution chart, Electromed ranks #999999 out of 325 companies in the Medical Devices & Instruments industry.
Is Electromed's 5-Year Yield-on-Cost % too high?
Electromed's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Electromed ranks #999999 out of 325 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Electromed has a GF Score™ of 91/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Electromed's 5-Year Yield-on-Cost % compare to CATX and MASS?
According to the Medical Devices & Instruments industry distribution chart, Electromed ranks #999999 out of 325 companies for 5-Year Yield-on-Cost %. This places Electromed in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.31, based on 325 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Electromed and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Electromed's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Electromed stock overvalued right now?
Based on GuruFocus' analysis, Electromed (ELMD) is currently considered Significantly Overvalued. The stock's GF Value™ is $25.34, compared to a current price of $42.80 — trading 68.9% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Electromed's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Electromed (ELMD), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Electromed (ELMD) Overvalued in 2026?
Based on GuruFocus' analysis, Electromed stock appears to be overvalued.
The current stock price of $42.80 is trading 68.9% above its estimated GF Value™ of $25.34.
GuruFocus considers Electromed to be Significantly Overvalued.
Key valuation signals for ELMD:
5-Year Yield-on-Cost %: 0.00
GF Value™: $25.34 vs. price of $42.80 (68.9% above fair value)
No single metric tells the full story. See the ELMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
91GF Score
Get the complete analysis for ELMD
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELMD has been successfully added to your 
